Aspirin For Benign Prostatic Hyperplasia: Studying The Effect On Flow-Rate By A Self-Designed Flowmeter
Keywords:
Aspirin, Benign prostatic hyperplasia, flow-rate, load cellAbstract
Objective: The study was conducted to determine the effect of acetylsalicylic acidor commercially called (Aspirin) on the flow rate of patients with benign prostatic hyperplasia by the use of a self-designed flowmeter.
Materials and Methods: This was a prospective study between May 2007 and September 2015, evaluating the effect of Aspirin 100 mg in patients with benign prostatic hyperplasia on prostate symptom score and the maximum flow rate, using a flowmeter designed and assembled by the author. The total number of patients completed the study was 1338 patient, they were all assessed and flow rate measured both before given Aspirin and after one-year time.
Results: The international prostate symptom score had a reduction in its mean from15.431 ±2.665 SD to14.352±2.455 SD after one year of taking Aspirin, the maximum flow rate was increased from7.66ml/sec ± 1.63 SD to9.26 ml/sec ± 1.96 SD in the same period.
Conclusion: Aspirin is effective in reducing the symptom score of patients with benign prostatic hyperplasia and improve the flowrate in such patients, using the economical self-designed and assembled flowmeter.
References
Pettaway C, Lamerato L, Eaddy M, et al. Benign prostatic hyperplasia: racial differences in treatment pattern and prostate cancer prevalence. BJU Int. 2011; 108: 1302-1308.
Kirby R. The natural history of benign prostatic hyperplasia: What have we learned in the last decade? Urology 2000; 56: 3-6.
De Nuzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011; 60: 106-117.
Tanasescu S, Leveseque H, Thuillez C. Pharmacology of Aspirin. Rev Med Interne 2002; 21: 18-26.
Jennifer L, Debra J, Michael E, et al. Protective association between non-steroidal anti-inflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiology 2006; 164:760-768.
Thru A, TeruhikoY,and Hiromi K. Effectiveness of a nonsteroidal anti-inflammatory drug for nocturea on patients with benign prostatic hyperplasia: A prospective non-randomized study of loxoprofen sodium 60 mg once daily before sleeping. Acta Med Okayama 2004; 58: 45-49.
Theyer G, Kramer G, Assmann I et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66: 96–107.
Curtis J,ClausG,RamiroC,et al. Chronic prostate inflammation is associated with severity and progression of benign prostatic hyperplasia ,lower urinary tract symptoms and risk of acute urinary retention. J Urol 2016; 196: 1-6.
Erol H, Beder N, Caliskan T, et al. Can the effect of antibiotherapy and anti-inflammatory therapy on serum PSA levels discriminate between benign and malign prostatic pathologies? UrolInt 2006; 76: 20–26.
SacitN,ErtugrulS,Osman K, et al.The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturea and sleep quality.Int. Braz J Urol 2013; 39: 657-662.
Mieg J, Mohr B, Barry M, et al. Risk factors for clinical benign prostatic hyperplasia in a community based population of healthy aging men. J ClinEpidimiology 2001; 54:935-944.
Kang D,AndriolG,Van de vooren R , et al .Risk behaviors and benign prostatic hyperplasia .BJU Int. 2004; 93:1241-1245.
Alcaraz A, Hammerer P, Tubaro A, et al. Is there evedince of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol. 2009; 55: 864-875.
Sutcliffe S ,Platz E. Inflammation and prostate cancer : A focus on infections. Current Urol reports 2008; 9: 243-249
